Healthcare -
Biotechnology - NASDAQ - CN
$ 0.95
-4.85 %
$ 18.1 M
Market Cap
-0.35
P/E
1. INTRINSIC VALUE
Balance Sheet
LakeShore Biopharma Co., Ltd
| Current Assets | 903 M |
| Cash & Short-Term Investments | 246 M |
| Receivables | 447 M |
| Other Current Assets | 210 M |
| Non-Current Assets | 610 M |
| Long-Term Investments | 0 |
| PP&E | 481 M |
| Other Non-Current Assets | 129 M |
| Current Liabilities | 802 M |
| Accounts Payable | 67.8 M |
| Short-Term Debt | 324 M |
| Other Current Liabilities | 411 M |
| Non-Current Liabilities | 126 M |
| Long-Term Debt | 101 M |
| Other Non-Current Liabilities | 24.8 M |
EFFICIENCY
Earnings Waterfall
LakeShore Biopharma Co., Ltd
| Revenue | 573 M |
| Cost Of Revenue | 118 M |
| Gross Profit | 456 M |
| Operating Expenses | 902 M |
| Operating Income | -446 M |
| Other Expenses | -12.4 M |
| Net Income | -433 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
LakeShore Biopharma Co., Ltd
| Net Income | -433 M |
| Depreciation & Amortization | 42.2 M |
| Capital Expenditures | -44.3 M |
| Stock-Based Compensation | 9.79 M |
| Change in Working Capital | -45.8 M |
| Others | 193 M |
| Free Cash Flow | -339 M |
Wall Street Analysts Price Targets
LakeShore Biopharma Co., Ltd
LSB has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
LSB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
LakeShore Biopharma Co., Ltd
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
LSB Industries, Inc. to Participate in UBS Energy Transition and Decarbonization Conference on Wednesday, May 14th
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB” or the “Company”), today announced that its Vice President of Clean Energy, Jakob Krummenacher, will participate in the UBS Energy Transition and Decarbonization Conference in New York City on Wednesday, May 14th. Mr. Krummenacher will be available for one-on-one meetings all day at the conference. Additionally, Mr. Krummenacher will be participating in a panel discussion, “Scaling Carbon Capture Solutions Across Industry”.
businesswire.com
- 1 month ago
LSB Industries, Inc. Reports Operating Results for the 2025 First Quarter
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB,” “we,” “us,” “our,” or the “Company”) today announced results for the first quarter ended March 31, 2025. First Quarter 2025 Results and Recent Highlights Net sales of $143.4 million compared to $138.2 million in the first quarter of 2024 Net loss of $1.6 million compared to a net income of $5.6 million in the first quarter of 2024 Diluted EPS of $(0.02) compared to $0.08 for the first quarter of 2024 Adjusted EBITDA(1) of.
businesswire.com
- 1 month ago
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)
Revolutionizing Vaccination Safety with Needle-Free Reconstitution Technology BEIJING , April 23, 2025 /PRNewswire/ -- On April 18, 2025, LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company") successfully held the 2025 CSO ("Contract Sales Organization") Annual Meeting and the launch meeting of YSJA™ rabies vaccine (Vero cell) novel packaging solution (liquid drug transfer device) in Changsha, Hunan Province.
prnewswire.com
- 1 month ago
LSB Industries, Inc. Schedules 2025 First Quarter Results Release for Tuesday, April 29th and Conference Call for Wednesday, April 30th
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB”) (NYSE: LXU), today announced that it will release its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 after the close of the stock market. LSB's management will host a conference call on Wednesday, April 30, 2025 at 10:00 am ET / 9:00 am CT to discuss these results. Participating in the call will be Chairman, President & Chief Executive Officer, Mark Behrman, Executive Vice President & C.
businesswire.com
- 2 months ago
LSB Industries, Inc. Appoints Riccardo Bertocco as an Independent Member of the Board of Directors
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB” or the “Company”), today announced that it has appointed Riccardo Bertocco as an independent member of the Board of Directors (“the Board”) of the Company effective April 9, 2025. Mr. Bertocco will stand for direct election by shareholders for the first time at the annual meeting of stockholders on May 15, 2025 (the “2025 Annual Meeting”). Mr. Bertocco has worked extensively in management consulting for more than 25 years,.
businesswire.com
- 2 months ago
LSB Industries, Inc. Reports Operating Results for the 2024 Fourth Quarter and Full Year and Provides Product Sales Volume Outlook for 2025
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB,” “we,” “us,” “our,” or the “Company”) today announced results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Results and Recent Highlights Net sales of $134.9 million compared to $132.6 million in the fourth quarter of 2023 Net loss of $9.1 million compared to a net loss of $5.3 million in the fourth quarter of 2023; the fourth quarter 2024 net loss included approximately $17.1 million of.
businesswire.com
- 3 months ago
LSB Industries, Inc. Schedules 2024 Fourth Quarter and Full Year Financial Results Release for Wednesday, February 26th and Conference Call for Thursday, February 27th
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB”) (NYSE: LXU), today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, February 26, 2025 after the close of the stock market. LSB's management will host a conference call on Thursday, February 27, 2025 at 10:00 am ET / 9:00 am CT to discuss these results. Participating in the call will be Chairman, President & Chief Executive Officer, Mark Behrman, Executi.
businesswire.com
- 4 months ago
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoY Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY Gross margin increased to 82.6% from 80.9% in the same period of FY2024 Total operating expenses decreased to RMB 276.4 million, down 31.6% YoY Recorded net income of RMB 20.6 million, and adjusted net income[1] (Non-GAAP) of RMB 30.4 million, compared to net loss and adjusted net loss[1] (Non-GAAP) of RMB 174.5 million in the same period of FY2024 BEIJING , Dec. 19, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its financial results for the first six months ended September 30, 2024 ("FY2025H1").
prnewswire.com
- 5 months ago
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China
BEIJING, Dec. 12, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a leading global biopharmaceutical company focused on the innovation and production of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Shenyang Municipal Public Security Bureau in China (the “Bureau”) has initiated criminal investigations into actions taken by former chairman of the board of directors Yi Zhang (“Former Chairman”).
globenewswire.com
- 6 months ago
LSB Industries Announces Publication of 2023 Sustainability Report
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB” or “the Company”), (NYSE: LXU) today announced the publication of its 2023 Sustainability Report, highlighting the Company's progress in advancing its sustainability efforts. LSB remains focused on its vision of being a leader in the clean energy transition through the production and delivery of low carbon products to multiple end markets. Additionally, the Company prioritizes its involvement in activities that support the long-term su.
businesswire.com
- 6 months ago
LSB Industries, Inc. Appoints John Chandler as an Independent Member of the Board of Directors
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB” or “the Company”), (NYSE: LXU) today announced that it has appointed John Chandler as an independent member of the Board of Directors (the “Board”) effective November 7, 2024. Mr. Chandler was also appointed to the audit committee of the Board. Mr. Chandler has more than 30 years of experience in the energy industry, predominantly in financial leadership and business development roles. Most recently, he served as Chief Financial Office.
businesswire.com
- 7 months ago
LSB Industries, Inc. Reports Operating Results for the 2024 Third Quarter
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB” or the “Company”) today announced results for the third quarter ended September 30, 2024. Third Quarter 2024 Results and Recent Highlights Net sales of $109.2 million compared to $114.3 million in the third quarter of 2023 Net loss of $25.4 million compared to a net loss of $7.7 million in the third quarter of 2023; the third quarter 2024 net loss included approximately $16.3 million of turnaround costs and approximately $5.
businesswire.com
- 7 months ago
8. Profile
Summary
LakeShore Biopharma Co., Ltd LSB
COUNTRY
CN
INDUSTRY
Biotechnology
MARKET CAP
$ 18.1 M
Dividend Yield
0.00%
Description
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.
Contact
Building No. 2, Beijing, 102629
https://www.ysbiopharm.com
IPO
Date
Aug. 5, 2021
Employees
758
Officers
Ms. Rui Yu M.B.A., M.S.
Chief Financial Officer & Director
Dr. Yuan Liu Ph.D.
Head of Vaccine Research
Mr. Wang Xu
Chief Executive Officer & Director
Dr. Zenaida Reynoso Mojares M.D.
Chief Medical Officer
Ms. Zhiyuan Ran
Head of Medical & Marketing Department
Dr. Hui Shao C.F.A., M.B.A., Ph.D.
President, Chief Business Officer & Vice Chairman